Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Property Solutions Acquisition II (PSAGU)
Khosla Ventures Acquisition Co. (KVSA)
Twin Ridge Capital Acquisition (TRCA.U)
Rxr Acquisition (RXRAU)
Interprivate II Acquisition (IPVA.U)
Interprivate III Financial Partners (IPVF.U)
Aurora Acquisition Corp. (AURCU)
ALTIMAR ACQUISITION CORP. III (ATAQU)
Lerer Hippeau Acquisition Corp. (LHAA)
Universe Pharmaceuticals (UPC)
Roblox Corporation (RBLX)
First High-school Education Group Co., Ltd. (FHS)
Coupang, Inc. (CPNG)
Hayward Holdings, Inc. (HAYW)
Priced IPO
Innovage Holding Corp (INNV)
Oscar Health, Inc. (OSCR)
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
More companies

Abcellera Biologics, Inc. (ABCL)

Sector - Healthcare

Price chart

+50%
Return from IPO

Company News

IPO Profile

About company

They believe that the surest path to a better future is through technological advancement and that the new frontier of technology lies at the interface of computation, engineering and biology. Their mission is to improve health with technologies that transform the way that antibody-based therapies are discovered. They aim to become the centralized operating system for next generation antibody discovery. Their full-stack, artificial intelligence-, or AI, powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. They believe their technology increases the speed and the probability of success of therapeutic antibody discovery, including enabling discovery against targets that may otherwise be intractable. Rather than advancing their own clinical pipeline of drug candidates, they forge partnerships with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies. They empower them to move quickly, reduce cost and tackle the toughest problems in drug development. As of September 30, 2020, they had 94 discovery programs that are either completed, in progress or under contract with 26 partners.
Industry
Pharmaceuticals
CEO CFO
Carl L. G. Hansen Andrew Booth
Employees Founded
174 2012

Contacts

Address: 2215 Yukon Street Vancouver, British Columbia, V5Y 0A1, Canada

Telephone: (604) 559-9005

Web page: http://www.abcellera.com

IPO information

Expected Date 12/11/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 23
Shares Revised (MM) 24.2
Expected offer amount (MM) $356.5
Realized offer amount(MM) $484

Financial Data (last reporting year)

Market Cap (MM) $4640.5
Revenues (MM) $20.5
Net Income (Loss) (MM) $0.2

Voting

What do you think will happen with the ABCL share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Credit Suisse

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Credit Suisse/ Stifel/ Berenberg/ SVB Leerink/ BMO Capital Markets
CO-Managers
-

Sector: Healthcare

Tweets about $ABCL

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats